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Abstract
Trending and Thriving, CRISPR/Cas has expanded its wings towards diagnostics 
in recent years. The potential of evading off targeting has not only made CRISPR/
Cas an effective therapeutic aid but also an impressive diagnostic tool for various 
pathological conditions. Exosomes, 30 - 150nm sized extracellular vesicle present 
and secreted by almost all type of cells in body per se used as an effective diagnostic 
tool in early cancer detection. Cancer being the leading cause of global morbidity 
and mortality can be effectively targeted if detected in the early stage, but most of 
the currently used diagnostic tool fails to do so as they can only detect the cancer 
in the later stage. This can be overcome by the use of combo of the two fore men-
tioned diagnostic aids, CRISPR/Cas alongside exosomes, which can bridge the gap 
compensating the cons. This chapter focus on two plausible use of CRISPR/Cas, 
one being the combinatorial aid of CRISPR/Cas and Exosome, the two substantial 
diagnostic tools for successfully combating cancer and other, the use of CRISPR in 
detecting and targeting cancer exosomes, since they are released in a significant 
quantity in early stage by the cancer cells.




Amongst the non-communicable diseases, cancer remains to be the major 
cause of morbidity and mortality globally. As per the GLOBOCAN index 2020, 
19.3 million new cancer cases have been reported with around 10.0 million cancer 
deaths in 2020. Amongst the top 10 cancers, Lung cancer is considered leading 
cause of mortality with 18.0% of the total cancer deaths, followed by colorectal 
cancer with the death rate 9.4%, liver with the mortality rate of 8.3%, stomach with 
7.7%, and female breast cancer with the death rate of 6.9% (Figure 1) [1]. Cancer, 
by definition is considered as a condition characterized with uncontrolled divi-
sion of particular cell type in a definite site anywhere in the body as an aftermath 
of various triggering factors technically termed as Carcinogens, which have the 
ability to convert proto - oncogenes to Oncogenes causing cancer. Cancer cells can 
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divert metabolites into anabolic pathways to support their rapid proliferation and to 
accumulate the cellular building blocks required for tumor growth and differ mor-
phologically from other normal cells. It is reported that only around 5 – 10% total 
cancer is caused due to genetic defects such as BRCA1 and BRCA2 gene mutation in 
case of breast and ovarian cancer. Whereas, the other 90% is due to external factors 
such as exposure to potent carcinogens, lifestyle factors such as diet, stress, obesity, 
infections etc. [2–5].
WHO has broadly classified these carcinogens into physical (UV and other 
ionizing radiations), Chemical (alcohol, tobacco smoke, aflatoxins and various 
laboratory chemicals), Biological (Viruses such as Human Papilloma virus, hepatitis 
B virus, HIV etc., bacteria such as Helicobacter pylori, Mycobacterium tuberculosis 
etc., and parasites such as Schistosoma haematobium) and environmental (Air pol-
lutants) factors [6]. The uncontrolled growth of cells when occur in a solid tissue 
such as in an organ or muscle are termed as tumors. All tumors not necessarily be 
cancerous, the tumors are further classified into benign tumors, which are noncan-
cerous, devoid of spreading and malignant tumors, which are the cancerous ones 
that have the potential to spread to a distant organ via blood stream [7]. Cancer cells 
are known to invade adjoining parts of the body and spread to other organs to form 
the secondary tumor and this process is termed as metastasis, the primary cause of 
death from cancer.
Histologically, WHO has broadly classified cancers into following main catego-
ries viz.… Carcinoma (Cancer of epithelial tissue), Sarcoma (cancer of connective 
tissue), Myeloma (cancer of plasma cells of bone marrow), Lymphoma (cancer of 
lymphatic system), Leukemia (liquid cancer or cancer of blood), melanoma (cancer 
of pigment cells) and mixed types. Carcinoma accounts for around 180 – 90% of all 
cancer cases and are further sub divided into two categories such as Adenocarcinoma 
and squamous cell carcinoma [8, 9].
TNM (Tumor node metastasis) classification system, created in 1958 by the 
American Joint Committee on Cancer (AJCC) and the Union for International 
Cancer control (UICC) is yet another widely used system that classifies malignant 
tumor based on tumor spreading. It usually scores the size of the primary tumor 
(T), degree of spreading to the lymph node (N) and the presence of distant metas-
tasis (M). Based on different combinations of T, N and M, cancer has been catego-
rized into different stages 0 – IV for the aid of clinicians to establish the anatomic 
extent of infection. The stage 0 represents carcinoma in situ with the combination 
Tis, N0, M0 and are considered noncancerous but with the possibility of becom-
ing one. Whereas, Stage I represents localized cancer with the TNM combination 
Figure 1. 
Global incidence rate and death rate.
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of T1-T2, N0, M0. Stage II is referred to locally advanced cancer with early stages 
and combination of T2-T4, N0, M0. While Stage III is characterized with locally 
advanced cancer, late stages with the combination T1-T4, N1-N3, M0, here the 
cancer would have been progressed with respect to the size of the tumor as well as 
it would have been spread to the adjacent lymph nodes. The stage IV is considered 
as the most severe stage, which is metastatic cancer with the combination, T1-T4, 
N1-N3, M1 [7, 10–12]. It is reported by that the above staging system is associated 
with severity of the disease and the survival rate of the patients, which is indirectly 
proportional i. e., higher the cancer stage so will be the severity of the disease 
and lesser will be the survival rate. For instance, 5-year survival rate of colorectal 
carcinoma at stage I is around 74% whereas, at stage IV it is only of 5% [10].
The signs and symptoms of cancer includes loss of appetite, extreme fatigue, pain 
in certain areas, persistent coughing, sudden loss of weight, blood in sputum, urine 
or stool, lumps on neck, breast, testicle etc. that does not hurt, changes in skin color-
ation, texture in certain areas etc. These fore said symptoms may not all ways point 
towards cancer, it could be due to any other pathological conditions too, but are the 
ones that should not be ignored [13, 14]. Currently there are several diagnostic tools 
in use for the detection of cancer such as laboratory testing of blood and urine for 
unusual blood count and for the detection of cancer biomarkers such as CA 125, CA 
19-9, CA-15-3, CD117, CD19, CD 20, HE4, alpha-fetoproteins (AFP), bladder tumor 
antigen (BTA) etc. [15, 16]. Noninvasive Imagining tests includes CT scan, X-ray, 
mammography, ultrasound, Positron emission tomography (PET) etc. and more 
invasive method of biopsy which is considered as the golden standard for cancer 
diagnosis. However these diagnostics tools are not devoid of their own cons as most 
of them only detect cancer in its later stages leading to poor treatment efficiency [17].
The available treatment options for cancer includes surgical removal of solid 
tumor, Chemotherapy, Radiation therapy, Gene therapy, hormone therapy, 
immuno therapy, bone marrow transplantation, targeted drug therapy etc. Based 
on the severity, resistance of the cancer cells towards any of the above mentioned 
therapeutic options and in order to avoid cancer relapse, a combination of the fore 
said therapies will be used as an adjuvant therapy. For instance surgical removal 
in combination with chemotherapy and radiation therapy are practiced in order to 
avoid recurrence rate of the cancer [18].
1.2 Exosomes
Exosomes, the nanosized extracellular vesicles ranging 30 - 150 nm, are 
known to be secreted by all most all types of cells into the extracellular space 
and are present in all body fluids viz.… blood, tears, saliva, sputum, pleural 
fluid/effusions, cerebrospinal fluid (CSF), breast milk, amniotic fluid, semen, 
urine etc. [19, 20]. First discovered in the year 1983 by Stahl and Johnstone 
independently in reticulocytes, these extracellular vesicles were later termed 
as “Exosomes” by Rose Johnstone in the year 1987 [21–23]. The exosomes are 
reported to be encompass bimolecular components such as proteins, lipid, DNA, 
RNA (both coding as well as non-coding), metabolites and various enzymes 
etc. recapitulating the parent cell. Morphologically, exosomes are cup shaped 
extracellular vesicles where the central lumen composing the cargo of variety of 
fore mentioned biomolecules will be surrounded by the lipid bilayer structure. 
Accounting for the presence of these cargo, these nano scaled endocytic vesicles 
has engrossed plethora of attention amongst the scientific community around the 
globe, for its remarkable role as an efficient diagnostic tool [24–26].
The exosomes are known to be produced more in cancer cells than that of 
normal cells. The tumor derived exosomes are mainly involved in the cell–cell 
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communication between cancer cells with both adjacent as well as distant cells as 
they gets secreted to the extracellular space and travel to a longer distant organ and 
tissue via blood stream facilitating cancer proliferation, Metastasis, drug resistance 
and immunomodulation. Apart from being involved in the dynamic crosstalk 
between the cells exosomes also proves to be an ideal drug delivery system with 
benefits such as specificity, safety and stability, since they are small and native to 
animals, they are able to avoid recognition and premature degradation by body’s 
immune defense mechanism. In recent years, exosomes are emerging as a promis-
ing biomarker tool as they carry specific genetic information and influence tumor 
growth and progression [27, 28].
1.3 CRISPR/Cas
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas 
(CRISPR associated endonuclease), a remarkable genome editing tool, has garnered 
plethora of interest of researchers in the field of modern gene therapy. Ever since the 
discovery of CRISPR locus in E. coli in the year 1987, several molecular biologists have 
shown tremendous interest and effort in characterizing and developing this wonder 
technique whereas, the noble prize for the development of this gene editing tool was 
bagged by Emmanuelle Charpentier and Jennifer Doudna in the year 2020 [29].
The CRISPR/Cas system is thought to be evolved from the prokaryotes such 
as bacteria and archaea as part of their adaptive immune system for combating 
viral infections. Precisely, they use a fragment of previously invaded viral genome 
called “spacer” as a source to memorize and defend any future attack by destroying 
the DNA from the similar viral particle, in association of Cas protein, which is an 
endonuclease enzyme, a molecular scissor to cut the double stranded DNA at a 
specific location on the target genome. It is reported that the CRISPR/Cas array is 
made of AT rich leader sequence, which is fenced by a set of Cas genes encoding 
the Cas proteins. The CRISPR/Cas is known to act through inducing site-specific 
DNA double stranded breaks and are known to surpass the other genome edit-
ing tools such as meganucleases, zinc finger nucleases (ZFNs), transcription 
activator like effectors (TALENs) etc., in being more precise, faster, efficient and 
inexpensive.
To brief out the conventional mechanism through which CRISPR/Cas executes 
their genome editing the following mechanism of gene editing pertaining to 
involvement of CRISPR/Cas9 has been described as follows, the CRISPR/Cas9 
system is said to be RNA guided DNA targeting endonuclease system, which works 
through sequence specific manner. The mechanism of CRISPR/Cas9 based genome 
editing has been divided into three main stages viz.… I) DNA acquisition from the 
invading phage particle (adaptation). II) Biogenesis of CrRNA or CRISPR/Cas 
assembly formation and III) target DNA annihilation or interference of the target 
DNA and Insertion of desired gene sequence (i. e., either knock out or knock in). 
briefly, a small fragment or scrap of foreign invading genome termed spacer gets 
incorporated genomic CRISPR array and gets transcribed during the process of 
adaptation or in the 1st stage leading to the synthesis of crRNA, which in turn gets 
bound to Cas endonucleases enabling specificity towards the target.
The advantage of CRISPR/Cas system over the other gene editing platforms 
are, it has the property of multiplicity, simple, easy to prepare and use, as only 20 
nucleotides in the guide RNA needs to be changed in order to retarget the Cas in 
CRISPR/Cas which in case of ZFNs and TALENs goes beyond 500-1500 base pairs. 
The CRISPR/Cas system can use multiple guide RNAs for targeting multiple target 
sites simultaneously in the same cell at the same time. This justifies the property of 
multiplicity of CRISPR/Cas system [29–35].
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2. Types of CRISPR/Cas systems and their applications
Based on the type Cas protein involved and the complexity of components the 
CRISPR/Cas system is divided into two classes viz.… Class I and Class II and are 
further classified into six types which are in turn categorized into 22 sub types. The 
class 1 classification that comprises of type I, III and IV are characterized to be con-
taining the involvement of multiple Cas proteins are whereas, class II classification 
are reported to comprise types II, V and VI where, only one effector Cas protein 
will be associated alongside the CRISPR array of processed guide RNA or in other 
words crRNA. Accounting for their nature of simplicity, the types involved under 
Class II Classification of CRISPR/Cas are reported to be the easiest in using for 
effective genome edited and manipulation of nucleic acids devoid of cells. Apart 
from being involved in gene editing the types of CRISPR/Cas systems derived from 
Class2 classification i. e., type II, V and VI are said to be instrumental in develop-
ing competent diagnostic platform of disease detection [36]. Brief representation 
of the fore said classification along with their application pertaining to class II 
CRISPR/Cas is as follows, Figure 2.
3. Exosomes in diagnosis
As mentioned prior in the introduction, exosomes are the nanosized form of 
extracellular vesicle of 30-150 nm size synthesized through a endosomal pathway 
via involvement of early, late endosomes and multi vesicular bodies (MVB) and are 
known to encompass several proteins lipids, nucleic acids etc. as their cargo. The 
exosomes are said to be involved in several biological processes such as, these are 
involved in cell–cell communication by the virtue of its cargo of fore mentioned 
compounds in the introduction both in physiological as well as pathological condi-
tions. In pathological conditions including cancer, the cancer cell derived exosomes 
are reported to be synthesized or secreted in larger quantity than that from the 
normal cells, these cancer cell derived exosomes are considered key players in 
tumor growth and metastasis and are thought to be involved in stimulation of 
immune response. Apart from these, the exosomes are also suggested to be the part 
of dynamic cross talk between cancer cells and surrounding normal cells such as 
Figure 2. 
Classification of CRISPR/Cas system with their emphasized application.
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fibroblasts, endothelial cells, mesenchymal cells etc., and are considered to play an 
important role mediating resistance towards therapy [26, 27].
The biomarkers are any biochemical component of the body, whose presence 
can be used as an indication of certain pathological condition. A cancer biomarker 
are known to represent any molecule or a process that shows the existence of tumor 
or cancer in the body. Cancer exosomes are one such components, which in recent 
years have gained tremendous importance as a liquid biopsy tool as these exosomes 
are exact representation of their parent cell in terms of their cargo and reflects the 
altered state of the parent cell. The cancer exosomes are known to contribute to can-
cer progression via enhancement of intercellular transfer of their cargo within the 
tumor microenvironment. These minimally invasive biomarkers are more conve-
nient over the conventional tissue biopsy involving surgery in being highly sensitive 
and specificity and are involved in early detection of cancer as these exosomes 
are required for the metastatic niche formation that can be accomplished by their 
release to the circulatory system from where they can be detected [26, 37, 38].
Isolation and characterization of exosomes are consider a very crucial step in 
diagnostics and biomarker development. Several techniques have been employed 
for an efficient isolation of these exosomes which includes classical ultracentrifuga-
tion (differential ultracentrifugation), precipitation based isolation (exosome isola-
tion kits), using size exclusion chromatography, filtration based isolation, using 
immunomagnetic isolation method etc. Followed by their isolation these exosomes 
can be characterized for their number, size and zeta potential value by using instru-
ments such as nano trafficking analysis (NTA), Dynamic light scattering (DLS), 
and for the morphological feature using SEM, TEM etc. [38–42].
The subsequent proteomic analysis of the isolated exosomes from the cancer 
cells have reported to shed light in identification of potent exosomal biomarker in 
several cancer types such as breast, lung, liver, prostate, ovarian, colorectal cancer, 
glioblastoma etc., the specific exosomal proteins includes surface proteins, Rab 
family GTPases, annexins, flotullin, exosome biogenesis proteins such as, Alix, 
Tsg101 and ESCRT complex. Several other exosomal protein includes, Tetraspanins 
(CD63, CD9, CD81, CD53etc.), Hsp90, Hsp70, EpCam etc. can serve as an efficient 
exosomal markers. A study by Rupp et al. Has reported the exosomal CD24 could 
serve as an efficient circulating biomarker for the detection of breast cancer. Several 
other exosomal protein biomarkers reported in breast cancer diagnosis are EDIL3 
and fibronectin, for early breast cancer detection using ELISA, which can also serve 
as treatment response marker as the level of these two tremendously decreased after 
surgery. Likewise the expression of Survivin, a apoptosis inhibitor was found to be 
higher in prostate cancer exosomes compared to the normal. The urinary exosomes 
also do possess significant amount of biomarker such as PCA3, TMPRSS2: ERG in 
prostate cancer [38, 43–46].
Several recent studies have reported the development of numerous exosome-
based diagnostic platform viz.… Exochip, which is a microfluidic device devel-
oped by Kanwar and team based on the exosomal tetraspanin protein CD63 
where, the exosomes gets bound with CD63 antibody and a fluorescent reporter 
using which, the exosomes can be quantified. Another type of analytical tech-
nique used in exosome diagnostics is ExoScreen, the technique developed by 
Yoshioka et al., that utilizes CD9 and CD147 antibodies alongside photosensitizing 
beads. Apart from the above two, yet another exosome diagnosing tool was devel-
oped by Zhao and team called Exosearch chip which is a comparatively simpler 
technique which enables the quantitative isolation of exosomes by the virtue of 
immunomagnetic beads. The Exosearch technique was successfully used for the 
quantification of ovarian cancer exosomes using the exosomal markers CA-125, 
EpCam and CD24 [38, 47–49].
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Apart from exosomal proteins, the use of techniques such as RNA-sequencing 
and DNA sequencing for the analysis of genomic data of cancer-derived exosomes 
have shed light on yet another exosomal component as an efficient biomarker 
use i. e., nucleic acid especially the ncRNAs including miRNAs and lncRNA. The 
exosomal miRNA are considered a most appropriate exosomal biomarker as they 
are quite stable against Rnase dependent degradation. Till date numerous exosomal 
miRNAs have been characterized as a potent tumor marker in several cancer condi-
tions to name a few are, miR-21, miR-141, miR-220a, miR-200b, miR-203, miR-205, 
miR-214 in case of ovarian cancer as reported by Taylor et al. Other examples for 
exosomal miRNA biomarkers includes miR-31, miR-196a, miR-1246, miR-191, 
miR-451a, miR-483-3p, miR-16a etc. in case of pancreatic cancer have also been 
reported by several studies. Other ncRNAs accounting for exosomal long noncod-
ing RNA, circular RNA have also been reported pertaining to the development of 
exosomal biomarkers for early cancer detection [38, 50–52].
4. CRISPR in diagnosis
Along with its extensive use in the field of genome editing, CRISPR/Cas system 
has expanded its wings towards diagnostics where it is mainly involved in detection 
of specific nucleic acid such as genomic DNA, non-genomic DNA, RNA, and patho-
genic microbe genomes. This could have been accomplished due to their natural 
ability of efficient nucleic acid recognition and editing, have been demonstrated to 
be extraordinary tools for specific nucleic acid detection. The CRISPR diagnostics 
are reported to have influence the targeting efficiency of the CRISPR guide RNA 
either in the presence or absence of nucleic acid cleaving potential of the Cas 
nucleases. The basic principle of CRISPR based diagnostics is, here the CRISPR/Cas 
components are modified in such a way that, they will emit the color or fluorescence 
with response to their binding with the target nucleic acid sequence in certain patho-
logical conditions. Based on the involvement of specific effector protein, several 
CRISPR based diagnostic tools kits have been developed which are mainly belonging 
to class II of CRISPR/Cas classification viz.… dCas9, SHERLOCK, SHERLOCK v2, 
DETECTR, HOLMES for an efficient detection of pathological conditions. A brief 
characterization, mode of action, application and advancement of these CRISPR 
tool kits in general and with respect to cancer will be discussed in this section.
Being the first effector protein to be characterized, Cas9 not only plays a vital 
role in genome editing, rather with minor modifications such as in dCas9, which 
is a nuclease-deactivated Cas9 (also termed as dead Cas9), it is also reported to be 
involved in nucleic acid detection as a simple and programmed detection tool. The 
dCas9 system is designed with modification in the basic activity of the conventional 
Cas9 protein in terms of deactivating the nucleic acid cleavage potential and only 
retaining the specific binding ability to target dsDNA. This was accomplished by 
inducing two point mutations H840A and D10A in the HNH and RuvC nuclease 
domain of the conventional Cas9 effector protein [36, 53].
Alongside classy Cas9, three more novel class 2 effector Cas proteins Cas12a 
(prior referred as Cpf1), Cas13a (prior referred as C2c2)and Cas14a have been 
showed to have more potent diagnostic properties and have become the latest 
interest of the scientific community. Unlike the Cas9 nuclease, the latter mentioned 
effector proteins have the property of “Collateral cleavage”, the property in which 
they can induce cleavage of the nearby sequence, which is not complementary to 
the designed crRNA upon detection and binding to the target nucleic acid sequence. 
Precisely, the when crRNA along with its effector protein either Cas12a or Cas13a 
recognize and bind to their target nucleic acid sequence either DNA or RNA 
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followed by their cleavage the activated effector protein also cleaves the nearby non 
targeted RNAs which does not emit the fluorescence until it is cleaved. With this, 
they offer a simple, fast, portable and reliable quantitative detection in diagnostics. 
It is this property of Cas12a and Cas13a, which has enabled effective tracing and 
detection of specific nucleic acid sequence, where the fluorescent ssDNA/ssRNA 
reporters are cleaved as a result of collateral cleavage.
Cas12a, which is previously referred to as Cpf1, are the variant of Cas effec-
tor protein which are RNA-guided, DNA-targeting enzyme, involved in type V of 
CRISPR/Cas classification. Unlike Cas9, these are reported to act or detect, bind and 
cleaves ssDNA. In contrast to this, Cas13a, which is previously referred to as C2c2 
are RNA-guided targeting enzymes involved in type VI of CRISPR/Cas system and 
are specific for ssRNA. Based on the promiscuous Rnase ability of collateral cleav-
age of Cas12a as well as Cas13a several molecular diagnostic platforms have been 
developed in the recent years details of which will be discussed further [53–57].
As said before the collateral cleavage ability of Cas13a nuclease, lead to the devel-
opment of a versatile in vitro nucleic acid detection platform named Specific High 
sensitivity Enzymatic Reporter UnLocking or simply abbreviated as SHERLOCK by 
Feng Zhang et al. in the year 2018, through technique of isothermal amplification 
along with recombinase polymerase amplification and T7 transcription, which has 
a wide spread application detecting viruses, pathogenic bacteria and in identify-
ing tumor DNA mutation. Recent studies have reported the use of SHERLOCK in 
detecting two mutants BRAF V600E and EGFR L858R. An improved version of 
SHERLOCK, named SHERLOCKv2, was also came into existence with the ability 
to detect four viruses at the same time. Yet another CRISPR/Cas system involving 
Cas12a is also been found to be the basis of developing two more diagnostic tool, 
named DETECTR (DNA endonuclease targeted CRISPR trans reporter) by Doudna 
et al. in 2018. The former has been found instrumental in diagnosing HPV + ve cervi-
cal cancer subtypes HPV 16 and HPV18 in both cell lines as well as clinical samples 
from the patients [53]. Apart from the above another diagnostic platform based on 
Cas12a has be developed called, one-hour low-cost multipurpose highly efficient 
system or simply HOLMES in the same year. Further experimentation focusing on 
the use of other Cas enzymes, Cas14 as well as CasX, which are Cas variants of type 
V CRISPR/Cas system alongside Cas12a. Development of newer diagnostic platform 
using these exceptionally smaller and compact RNA – guided nucleases made of 400-
700 amino acids, targeting ssDNA are under progression for exploring their diagnos-
tic potential as Cas14-DETECTR, yet another tool by Doudna and team [58, 59].
FEATURES dCas9 SHERLOCK DETECTR
Characteristics cancer therapy by 
modifying DNA of 
target genes, stimulate 
tumor suppressor genes, 
knockdown oncogenes and 
tumor resistance pathways 
for targeted therapy
efficient, robust 
method to detect 
RNA and DNA, quick 
detection of infectious 
disease and involved in 
sensitive genotyping
genome editing tool 
based on its ability 
to stimulate genetic 
alteration in cells 
at sites of double-
stranded DNA cut
Type of Cancer Breast cancer, prostate 
cancer
Breast cancer Cervical cancer
Target gene AKT EGFR L858R and 
BRAF V600E
HPV16, HPV18
References [60] [57, 61, 62] [53, 59, 63]
Table 1. 
Different CRISPR tools used for diagnosis of cancer malignancy.
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5. Future of Exo CRISPR diagnostics
The two most important diagnostic markers Exosomes as well as CRISPR/Cas 
system and their features and advantages have been discussed thoroughly in the 
above sections. As mentioned before there are several exosome based diagnostic 
tools (ExoChip, ExoScreen, Exosearch) as well as CRISPR/Cas based diagnostic 
platforms (SHERLOCK, SHERLOCKv2, DETECTR and HOLMES) for the efficient 
diagnosis of the pathological conditions. Even though both of the fore said diag-
nostic platforms offers a greater advantage towards cancer diagnostics, these are 
not devoid of the cons pertaining to the exosomal detection, these are said to be in 
requirement of sophisticated sensing methodologies involving expensive equip-
ments, and kits. On the other hand the CRISPR/Cas system, are in requirement of 
a efficient delivery in order to minimize the degradation by the systemic enzymes. 
With this insight, we hereby, suggest the use of a combinational technique made of 
both Exosomes and CRISPR where one can circumvent the drawback of other and 
becoming a full-fledged diagnostic platform.
In order to achieving efficient delivery of CRISPR/Cas system towards its target 
is an important step in the process of diagnostics and hence developing novel 
delivery system with higher efficiency and low immunogenicity and cytotoxicity is 
essential for the diagnostic applications. Off target effect of CRISPR system might 
lead to false acquisition of data for getting rid of which, the system has to be prop-
erly directed towards the target cell to achieve accuracy and efficiency. Different 
types of delivery system are available in present days this includes Adeno-associated 
viruses, Adenoviral vector, Lentiviral vector, Microinjection, electrophoresis, Lipid 
nanoparticle, cell penetrating peptides mediated and Gold nano particle mediated 
approaches [64]. Exosome, are reported to act as a promising carrier for CRISPR 
delivery, have an advantage over the other delivery system due to their natural 
biocompatible characteristics, high stability, low immunogenicity, and long circula-
tion. Some exosomes can even have a high capacity to escape from degradation or 
clearance by the immune system [64, 65].
Recent advancement on this combinational approach has been reported by 
Yi He et al., and team where they have constructed a combinational tool called 
Aptamer-RPA-TMA-Cas13a Assay (ARTCA), a CRISPR/Cas13 based platform with 
modification for a significant detection of exosomal PD-L1 i. e., programmed cell 
death receptor, a promising biomarker for cancer immunotherapy monitoring, 
directly from the serum. This was accomplished by using an PD-L1 specific DNA 
aptamer which is further amplified by the aid of recombinase polymerase amplifica-
tion (RPA) which is intern coupled with TMA (transcription-mediated amplifica-
tion). By the aid of this tremendous diagnostic tool the expression level of PD-L1 
in circulating tumor exosomes was constructed as reliable biomarker detection 
system. The same team have also reported the use of Cas12a for the construction of 
yet another CRISPR/Cas strategy, termed the apta-HCR-CRISPR assay, in order to 
detect nucleolin+ ve and PD-L1 + ve tumor derived exosomes [66–68]. With this we 
hereby, summarize the use of Exosome/CRISPR/Cas combo, where the exosomes 
can be effectively used for the delivery of CRISPR targeting the detection of specific 
nucleic acid or the array where the CRISPR/Cas system can be efficiently be targeted 
for the detection of exosomal biomarkers enlisted in the prior sections for early 
detection of cancer. The precise mechanism of Exosome/CRISPR/Cas system has 
been depicted in Figure 3 where, the fore said combination can be used for both 
In vivo as well as In vitro diagnosis of tumor as picturized in Figure 3A. Here the 
exosomes derived from different sources can be used as a effective vehicle for site 
specific delivery of CRISPR/Cas detection system to avoid off target effect and false 
acquisitions. As depicted in Figure 3B, which is yet another possibility of using this 
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significant combination which can be optimized for Ex Vivo detection of cancer 
exosomal biomarkers that are secreted in early stages of cancer progression such 
as exosomal DNA, exosomal coding and noncoding RNAs (miRNA, lncRNA) and 
exosomal proteins. This can be beneficial for developing Exo CRISPR based early 
cancer detection kits.
6. Conclusion
It is generally stated, “The sooner, the better” which is more appropriate when it 
comes to diagnostics. If any pathological condition is detected in its earlier phases, 
the options for the effective treatment of that particular disease will be a lot more 
efficient than that of in the later phases. As mentioned in the fore said introduction, 
there are several diagnostic techniques available for the detection of cancer. Though 
these techniques offer a greater aid in the diagnosis of several pathological condi-
tions including cancer, these are not devoid of the disadvantages in being pricey, 
Figure 3. 
Schematic representation of mechanism of action of exosome/CRISPR/Cas system for efficient cancer 
diagnosis. A) Exosome mediated delivery of CRISPR/Cas for effective detection of cancer. B) CRISPR/Cas 
based detection of exosomal biomarkers for early cancer diagnosis.
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time consuming and they do pose the threat to cause infections leading to worsening 
of the condition. For instance, in case of biopsies, even though it is considered the 
golden standard in the cancer diagnosis, they do have the threat in causing infec-
tions as, it is an invasive method. The threat of repetitive exposure to the radiations 
such as x-rays might also effect otherwise along with being useful in diagnosis of 
solid tumors.
As mentioned before the greatest drawback of the conventional diagnostic tools 
when it comes to cancer is, most of these techniques can only detect the disease in 
its later stages. Such as, in case of laboratory techniques, which uses of blood and 
urine for the presence of conventional biomarkers enlisted above, can be detected 
in the later stages when cancer has already become metastatic as these biomarker 
enters the blood stream in the later stages. This is where the role of exosomes comes 
into play as an efficient biomarker for early cancer detection as, there are several 
reports stating that the exosomes from the cancer cells are secreted more compared 
to the exosomes secreted from the normal cells, in order to aid in further spread-
ing of the disease to the distant sites of the body. Moreover, these exosomes have 
unleashed the site for lesser - noninvasive method of diagnosis as it is present in all 
the body fluids enlisted in the introduction section.
Several research reports supports the use of CRISPR/Cas system for its sub-
stantial role in diagnosis. In recent years both exosomes as well as CRISPR/Cas 
per se has proven to be an excellent diagnostic aid. The CRISPR based diagnostics 
have unmatched advantages over the conventional diagnostic tools, and aided the 
researchers with its precision targeting efficiency, high specificity and single base 
specificity enabling early screening and detection of cancer susceptible genes and 
sensitivity towards the target nucleic acid and with its low time consuming and 
monetary costs. Here in this book chapter, we have summarized the possible com-
binatorial effect of these two tools, which might offer an additional competence. 
Detection of cancer in its early stages might be handy in improving the efficiency of 
its treatment and might reduce the possibility of cancer relapse as the recurrence rate 
is reported to be comparatively more in the later stages of cancer making it incurable.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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